Department of System Medicine, University of Rome Tor Vergata, Via Montpellier 1, Rome 00133, Italy.
Eur Respir J. 2012 Sep;40(3):724-41. doi: 10.1183/09031936.00213711. Epub 2012 Apr 10.
The hallmark of chronic obstructive pulmonary disease (COPD) is an enhanced or abnormal inflammatory immune response of the lungs to inhaled particles and gases, usually from cigarette smoke, characterised by increased numbers of neutrophils, activated macrophages and activated T-lymphocytes (Tc1 and Th1 cells). Therefore, suppression of the inflammatory response is a logical approach to the treatment of COPD. Despite the inflammatory nature of COPD, currently available anti-inflammatory therapies provide little or no benefit in COPD patients and may have detrimental effects. For this reason, there is an urgent need to discover effective and safe anti-inflammatory treatments that might prevent the relentless progression of the disease. In recent years, attention has largely been focused on inhibition of recruitment and activation of inflammatory cells, and on antagonism of their products. In this review, we put together a summary of the state-of-the-art development of clearly and/or potentially useful anti-inflammatory strategies in COPD.
慢性阻塞性肺疾病（COPD）的特征是肺部对吸入的颗粒和气体（通常来自香烟烟雾）产生增强或异常的炎症免疫反应，表现为中性粒细胞、活化的巨噬细胞和活化的 T 淋巴细胞（Tc1 和 Th1 细胞）数量增加。因此，抑制炎症反应是治疗 COPD 的合理方法。尽管 COPD 具有炎症性质，但目前可用的抗炎疗法对 COPD 患者几乎没有益处，甚至可能有不良影响。因此，迫切需要发现有效和安全的抗炎治疗方法，以防止疾病的无情进展。近年来，人们的注意力主要集中在抑制炎症细胞的募集和激活，以及拮抗其产物上。在这篇综述中，我们总结了 COPD 中明确和/或潜在有用的抗炎策略的最新进展。
